Sign In
Buy EQ
$3.11
+0.320 (+11.47%)
At Close: Jun 03, 2026
Will Equillium Continue to Surge Higher?
12:33pm, Tuesday, 28'th Jan 2020
As of late, it has definitely been a great time to be an investor in Equillium.
Equillium Sees Hammer Chart Pattern: Time to Buy?
03:01pm, Thursday, 09'th Jan 2020
Equillium has been struggling lately, but the selling pressure may be coming to an end soon.
Can The Uptrend Continue for Equillium?
02:52pm, Friday, 03'rd Jan 2020
As of late, it has definitely been a great time to be an investor Equillium
Hedge Funds Are Dumping Equillium, Inc. (EQ)
11:41pm, Sunday, 22'nd Dec 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks a
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand
12:00pm, Thursday, 12'th Dec 2019
Equillium Inc. (EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, and Biocon Ltd (BS
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
12:56pm, Tuesday, 10'th Dec 2019
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeut
Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
09:10pm, Monday, 09'th Dec 2019
Equillium, Inc. (EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced t
Equillium Shares March Higher, Can It Continue?
12:13pm, Monday, 09'th Dec 2019
As of late, it has definitely been a great time to be an investor Equillium.
Equillium, Inc. (EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced t
Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health
01:05pm, Friday, 15'th Nov 2019
Equillium, Inc. (EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced t
Equillium Announces Leadership Updates
09:07pm, Tuesday, 12'th Nov 2019
Equillium, Inc. (EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced t
Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights
09:05pm, Tuesday, 12'th Nov 2019
LA JOLLA, Calif., Nov. 12, 2019 -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe.
Equillium to Present at Investor Conferences in November 2019
09:07pm, Thursday, 07'th Nov 2019
LA JOLLA, Calif., Nov. 07, 2019 -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to.
